article thumbnail

The future of AI drug discovery & development in immunology and GPCR research

pharmaphorum

A mere six months ago Verily launched the study with Sosei Heptares – a global leader in GPCR structure-based drug design – with an aim to “prioritise protein targets for therapeutic targeting in immune-mediated disease”. Verily’s Immune Profiler can, Kim asserted, “generate more than 8 million immune measures across 24 immune cell subsets”.

article thumbnail

Alzheimer’s therapeutics market to reach $6.8 billion by 2032

European Pharmaceutical Review

In 2015, Alzheimer’s Therapeutics International found there was an estimated 46.8 According to Alzheimer’s Therapeutics International in 2015, 58 percent of people with dementia live in developing countries, but by 2050 this will rise to 68 percent. percent, and driven largely by collaboration of existing players, reach $6.8

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Ex-Merck & Co scientist accused of stealing trade secrets could face jail

pharmaphorum

Quadri, formerly Merck’s head of medical and scientific affairs, immune oncology, has been charged with one count of theft of trade secrets and one count of unauthorised transmission of trade secrets, some relating to the multi-billion dollar cancer immunotherapy Keytruda (pembrolizumab).

article thumbnail

The end-of-life care conundrum

pharmaphorum

The most prominent of such therapies are immune checkpoint inhibitors, such as the PD-1/PD-L1 therapies that have become some of the best-selling treatments across the industry. What did change was the use of chemotherapy (26% in 2015 and 16% in 2019), and the increase in the delivery of immunotherapy (5% in 2015 and 18% in 2019).

article thumbnail

Cancer vaccines: providing the edge in oncology

pharmaphorum

According to a report by IQVIA last year, there were 3,500 oncology-focused therapeutic candidates in the pipeline, which represents a 75% increase on figures seen in 2015. Using a vaccine to utilise the patient’s own immune system to fight cancer is particularly attractive because of the targeted approach made possible by this technology.

Vaccines 134
article thumbnail

IO Biotech raises $155m to develop breakthrough cancer vaccine

pharmaphorum

The Series B fundraiser follows the FDA’s decision to grant Breakthrough Therapy designation last month for a combination of its lead immune-oncology therapies IO102 and IO103, with anti-PD-1 monoclonal antibodies for patients with metastatic melanoma.

article thumbnail

The next generation of immunotherapy? Innate Pharma targets NK cells

pharmaphorum

Founded in 1999, Marseille-based company Innate Pharma is on a mission to develop immunotherapies that take advantage of the body’s innate immune system. The cytokine release prompts T-cells so they can translate that first innate immune response into a long-lasting adaptive immune response. About the interviewee.